FDA warns against popular anti-obesity drugs; including one Musk admitted taking

The Food and Drug Administration (FDA) recently approved Bayer's novel drug, Sunharbo, to reduce the recurrence of stroke, marking a significant advancement in an area with minimal innovation for decades. This new class of medications aims to prevent blood clots more safely, as many existing blood thinners pose an increased risk of bleeding. Sunharbo, sold under the brand name Sunharbo, utilizes a unique mechanism that effectively halts the formation of detrimental clots without exacerbating the risk of bleeding.

Secondary strokes affect approximately 20% of individuals who have experienced their first stroke, potentially resulting in severe disability or death. The FDA's approval of Sunharbo comes amid ongoing concerns over the safety of GLP-1 drugs, which have been associated with a rare yet severe eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), or "eye stroke."

This condition, characterized by insufficient blood flow to the optic nerve, typically leads to sudden vision loss and, in severe cases, can cause blindness. Currently, there are no established treatments for this ailment.

The FDA's warning stems from a 2024 observational study that linked Ozempic and Wegovy, popular GLP-1 drugs, to the development of NAION. Pharmaceutical companies are now required to disclose this risk to patients and healthcare providers. Despite the FDA's cautionary stance, the approval of Sunharbo represents a promising step forward in the realm of stroke prevention, offering a safer alternative to traditional blood thinners for those at risk of recurrent strokes.